{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:06:43Z","timestamp":1761901603180,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.msard.2019.101880","type":"journal-article","created":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T09:23:17Z","timestamp":1575278597000},"page":"101880","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["The clinical value of the albumin quotient in patients with neuromyelitis optica spectrum disorder"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7974-9051","authenticated-orcid":false,"given":"Bo","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuan","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan-Ji","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Man","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Long-Jun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bi-Tao","family":"Bu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai-Shi","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2019.101880_bib0001","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/jnnp.57.8.897","article-title":"Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report","volume":"57","author":"Andersson","year":"1994","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"10.1016\/j.msard.2019.101880_bib0002","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/ana.22421","article-title":"The blood\u2013spinal cord barrier: morphology and clinical implications","volume":"70","author":"Bartanusz","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2019.101880_bib0003","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/ana.21837","article-title":"Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo","volume":"66","author":"Bradl","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2019.101880_bib0004","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/BF00316151","article-title":"Protein profile of cerebrospinal fluid in multiple sclerosis with special reference to the function of the blood\u2013brain barrier","volume":"214","author":"Eickhoff","year":"1977","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2019.101880_bib0005","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/archneur.62.6.865","article-title":"Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement","volume":"62","author":"Freedman","year":"2005","journal-title":"Arch. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2019.101880_bib0006","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jamaneurol.2019.0905","article-title":"Association of intrathecal immunoglobulin G synthesis with disability worsening in multiple sclerosis","volume":"76","author":"Gasperi","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2019.101880_bib0007","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00415-004-0271-0","article-title":"Clinical characteristics, course and prognosis of relapsing Devic's Neuromyelitis Optica","volume":"251","author":"Ghezzi","year":"2004","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2019.101880_bib0008","first-page":"895","article-title":"Lack of blood\u2013brain barrier properties in microvessels of the prelaminar optic nerve head","volume":"42","author":"Hofman","year":"2001","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.msard.2019.101880_bib0009","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1177\/1352458514555785","article-title":"Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease","volume":"21","author":"Hoftberger","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2019.101880_bib0010","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1742-2094-7-52","article-title":"Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance","volume":"7","author":"Jarius","year":"2010","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.msard.2019.101880_bib0011","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrneurol.2010.72","article-title":"AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance","volume":"6","author":"Jarius","year":"2010","journal-title":"Nat. Rev. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2019.101880_bib28","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","article-title":"Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMA Neurology"},{"key":"10.1016\/j.msard.2019.101880_bib0012","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1212\/WNL.0b013e31826aac4e","article-title":"Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype","volume":"79","author":"Kitley","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2019.101880_bib0013","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12883-016-0564-9","article-title":"Albumin and multiple sclerosis","volume":"16","author":"LeVine","year":"2016","journal-title":"BMC Neurol."},{"key":"10.1016\/j.msard.2019.101880_bib0014","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jneuroim.2017.01.024","article-title":"Soluble CD40 ligand contributes to blood-brain barrier breakdown and central nervous system inflammation in multiple sclerosis and neuromyelitis optica spectrum disorder","volume":"305","author":"Masuda","year":"2017","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2019.101880_bib0015","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/brain\/awm047","article-title":"Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis","volume":"130","author":"Misu","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.msard.2019.101880_bib0016","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1212\/WNL.0b013e3181a82621","article-title":"A case of NMO seropositive for aquaporin-4 antibody more than 10 years before onset","volume":"72","author":"Nishiyama","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2019.101880_bib0017","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1474-4422(12)70133-3","article-title":"Aquaporin 4 and neuromyelitis optica","volume":"11","author":"Papadopoulos","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2019.101880_bib0018","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12974-015-0256-1","article-title":"Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype","volume":"12","author":"Probstel","year":"2015","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.msard.2019.101880_bib0019","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/ana.22686","article-title":"Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain","volume":"71","author":"Saadoun","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2019.101880_bib0020","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2019.101880_bib0021","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aai9111","article-title":"Glucose-regulated protein 78 autoantibody associates with blood\u2013brain barrier disruption in neuromyelitis optica","volume":"9","author":"Shimizu","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.msard.2019.101880_bib0022","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1212\/WNL.28.9_Part_2.76","article-title":"Multiple sclerosis: the blood\u2013brain.barrier and the measurement of de novo central nervous system IgG synthesis","volume":"28","author":"Tourtellotte","year":"1978","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2019.101880_bib0023","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1212\/WNL.30.3.240","article-title":"Multiple sclerosis: measurement and validation of central nervous system IgG synthesis rate","volume":"30","author":"Tourtellotte","year":"1980","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2019.101880_bib0024","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1177\/1352458515601903","article-title":"Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later","volume":"22","author":"Uher","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2019.101880_bib0025","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1155\/2006\/586306","article-title":"NMO-IgG: a specific biomarker for neuromyelitis optica","volume":"22","author":"Weinshenker","year":"2006","journal-title":"Dis. Mark."},{"key":"10.1016\/j.msard.2019.101880_bib0026","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurolology"},{"key":"10.1016\/j.msard.2019.101880_bib0027","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819309514?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819309514?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:49:03Z","timestamp":1761900543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034819309514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":28,"alternative-id":["S2211034819309514"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2019.101880","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The clinical value of the albumin quotient in patients with neuromyelitis optica spectrum disorder","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2019.101880","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101880"}}